Compare MPLX LP (MPLX) vs Novo Nordisk A/S (NVO) Price & Performance

MPLX LPTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

MPLX LP vs Novo Nordisk A/S — how do they compare? MPLX LP trades at $56.64 (market cap $57.97B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 3.8× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.54%). Which is the better fit depends on your goals.

	MPLX	NVO
Market Cap	$57.97B	$220.53B
Sector	Technology	Health
52-Week High	$59.17	$71.70
52-Week Low	$47.80	$35.29
Enterprise Value	$82.60B	$239.49B
Dividend Yield	7.54%	3.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MPLX LP

No Aura AI signal available yet.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.

Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MPLX

MPLX LP outperforms QQQ with 225% return in 5 years, driven by stable fee-based cash flows and strong distribution growth.24/7 Wall Street · 2 days agoBullish View details →

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 12 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 16 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

About MPLX LP

MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.